Manufacturers of 10 Drugs Slated for Medicare Price Negotiation Spent Billions More on Buybacks, Dividends and Executive Compensation than R&D
While the pharmaceutical industry says that the drug price negotiation provisions under the Inflation Reduction Act will harm research and development, a new report by Public Citizen and Protect our Care reveals that the manufacturers of the first 10 drugs selected for Medicare price negotiation spent $10 billion more on stock buybacks, dividends to shareholders, and executive compensation than they spent on research and development in 2022. According to the report, which analyzes SEC filings and company annual reports... Читать дальше...